Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233667 | 0.82 | TDP1 (0.52) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL7233114 | 0.80 | MEN1 (0.43) | RAB9AKMT2ATDP1MAPTKDM4E | |
| SCHEMBL7224180 | 0.77 | AR (0.37) | NPC1RAB9ASMN1; SMN2APEX1AR | |
| SCHEMBL6716647 | 0.75 | SMN1; SMN2 (0.51) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL2392285 | 0.70 | RAB9A (0.77) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL4759931 | 0.68 | NPC1 (0.62) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL6648102 | 0.68 | NPC1 (0.62) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL26778888 | 0.65 | KMT2A (0.50) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL26778956 | 0.65 | KMT2A (0.46) | NPC1RAB9AKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL24620479 | 0.64 | GAA (0.38) | KMT2ASMN1; SMN2MAPK1TDP1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| US-6329534-B1 | USEFUL FOR THERAPY OF TYPE II DIABETES, OBESITY, HYPERGLYCEMIA, INADEQUATE GLUCOSE CLEARANCE, HYPERINSULINEMIA, HYPERTRIGLYCERIDEMIA, AND HIGH-CIRCULATING GLUCOCORTICOID LEVELS | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | NPC1 586/4885RAB9A 4602/4885KMT2A 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.